HealthCare Global Enterprises Limited
₹584.80-₹6.45 (-1.1%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹9,408 Cr
- P/E
- 513.0x
- EV / EBITDA
- 49.9x
- Revenue
- ₹1,277 Cr
- Net margin
- 2.8%
- ROCE
- 10.4%
Price chart
Technical chartScreen technicals →-24.7% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -12.2%
- 3M
- -12.5%
- 6M
- +2.1%
- 1Y
- -24.7%
- 5Y
- +142.7%
52-week range
Day change -₹6.45 (-1.1%) from ₹591 to ₹585 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in HCG, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Strong short-term liquidity — current ratio of 4.11x
Concerns1
- Low return on equity of 2.8%
Rule-based from financial data. Not advice.
About the company
HealthCare Global Enterprises Limited provides medical and healthcare services in India and internationally.
Read moreShow less
HealthCare Global Enterprises Limited provides medical and healthcare services in India and internationally. The company offers cancer diagnostics services, including genomics and molecular diagnostics, digital PET, preventive oncology, physical examination, laboratory tests, home health services, digital pathology, and CTC detection; treatment services, such as medical oncology and haemato-oncology, radiation and surgical oncology, molecular imaging and theranostics, chemotherapy, robotic surgery, actinium and lutetium therapy, immunotherapy, psycho-oncology, targeted drug therapy, bone marrow transplant, pediatric oncology, organ preservation and reconstructive surgery, endocrine therapy, and liver transplant; and post care services comprising patient care, psychological support, nutrition and dietetics, multidisciplinary rehabilitation, and genetic counselling. It also provides cancer screening, interventional radiology, MRI, nephrology, clinical trial, hormone therapy, hematology, CAR T cell, translational and nuclear medicine, oncodermatology, anaesthesiology, paediatric and gynaecologic oncology, orthopaedic oncology, uro-oncology, infectious diseases, gastrointestinal and thoracic oncology, breast surgical oncology, clinical pharmacology, and pain and palliative services. In addition, the company operates multi-specialty hospitals under the HCG brand that offers inpatient and outpatient treatments with specialties in cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary, and critical care. Further, it provides oncology diagnostics services, including biomarker and translational research, and clinical research services under the Triesta Sciences brand; and fertility treatment services, including reproductive medicine, assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. HealthCare Global Enterprises Limited was founded in 1989 and is headquartered in Bengaluru, India.
- Sector
- Healthcare
- Shares outstanding
- 14.1 Cr shares
- ISIN
- INE075I01017
- BSE code
- 539787
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹9,408 Cr
- P/E
- 513.0x
- P/B
- 8.0x
- EV / EBITDA
- 49.9x
- EV / Sales
- 8.6x
- P/S
- 8.0x
- Earnings yield
- 0.2%
- 52-week high
- ₹777.55
- 52-week low
- ₹520.90
Profitability
- Operating margin
- 17.2%
- Net margin
- 2.8%
- EBITDA margin
- 17.2%
- ROE
- 2.8%
- ROCE
- 10.4%
- ROA
- 1.5%
- Dividend payout
- 0.0%
- Tax rate
- 39.0%
- Other income, % of PBT
- 0.0%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,277 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 9.1%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 11.2%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹201 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 6.9%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -87.9%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹209 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 60.8%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹243 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 29.4%
Solvency and efficiency
- Current ratio
- 4.11
- Debt / Equity
- 0.64
- Debt / Assets
- 0.34
- Debt / EBITDA
- 3.77
- Interest coverage
- 4.02
- Financial leverage
- 1.90
- CFO / Net profit
- 6.33
- Cash / Market cap
- 7.7%
- Cash per share
- ₹51.26
- Asset turnover
- 0.52
- Fixed asset turnover
- 1.20
- Capital intensity
- 0.83
- Debtor days
- 69 days
- Inventory turnover
- 12.17
- Cash conversion cycle
- -93 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹0 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹1,066 Cr |
| Sales | Operating profit | ₹211 Cr |
| Operating profit | Interest | ₹84 Cr |
| Operating profit | Depreciation | ₹111 Cr |
| Operating profit | Profit before tax | ₹16 Cr |
| Other income | Profit before tax | ₹4 Cr |
| Profit before tax | Tax and other | ₹16 Cr |
| Profit before tax | Net profit | ₹4 Cr |
Revenue and net profit
Revenue grew 9.1% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹609 Cr | -₹192 Cr |
| FY2022 | ₹850 Cr | ₹38 Cr |
| FY2023 | ₹1,006 Cr | ₹40 Cr |
| FY2024 | ₹1,171 Cr | ₹33 Cr |
| FY2025 | ₹1,277 Cr | ₹4 Cr |
Cash flows
FY2025: ₹146 Cr from operations, -₹201 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹71 Cr | -₹175 Cr |
| FY2022 | ₹124 Cr | ₹173 Cr |
| FY2023 | ₹130 Cr | -₹8 Cr |
| FY2024 | ₹209 Cr | -₹45 Cr |
| FY2025 | ₹146 Cr | -₹201 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹1,277 Cr+9.1%1Y
- Net profit
- ₹4 Cr-87.9%1Y
- Cash from operations
- ₹146 Cr
- Free cash flow
- -₹201 Cr
- Revenue CAGR, 5Y
- 11.2%
- EBITDA CAGR, 5Y
- 15.7%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹1,277 Cr | ₹211 Cr | — | ₹4 Cr | ₹146 Cr | -₹201 Cr | 0.3% | +9.1% | -87.9% |
Monthly returns
Month-by-month returns of HCG across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹2,604 Cr |
| Equity capital | ₹139 Cr |
| Reserves | ₹1,052 Cr |
| Borrowings | ₹1,118 Cr |
| Other liabilities | ₹295 Cr |
| Assets | ₹2,604 Cr |
| Fixed assets | ₹1,038 Cr |
| Capital work in progress | ₹23 Cr |
| Investments | ₹696 Cr |
| Other assets | ₹847 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
HCG trades at 513.0x earnings against a peer median of 52.6x (a 875% premium).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| HealthCare Global Enterprises LimitedHCGthis companyP/E ↑ premium | ₹9,408 Cr | 513.0x | 8.0x | 2.8% | 49.9x |
| Metropolis Healthcare LimitedMETROPOLIS | ₹9,882 Cr | 74.0x | 7.4x | 11.3% | 36.5x |
| Sanofi Consumer Healthcare India LimitedSANOFICONR | ₹9,742 Cr | 45.3x | 37.8x | — | — |
| JYOTHY LABS LIMITEDJYOTHYLAB | ₹9,555 Cr | 27.2x | 6.6x | 32.4% | 17.6x |
| Sanofi India LtdSANOFI | ₹9,387 Cr | 25.4x | 12.0x | — | — |
| Jeena Sikho Lifecare LimitedJSLL | ₹8,968 Cr | 58.2x | 25.2x | 35.9% | 90.3x |
| PROCTER & GAMBLE HEALTH LIMITEDPGHL | ₹8,946 Cr | 29.2x | 14.4x | — | — |
| Jupiter Life Line Hospitals LimitedJLHL | ₹8,877 Cr | 46.3x | 5.9x | 12.2% | 34.5x |
| Corona Remedies LimitedCORONA | ₹8,749 Cr | 55.1x | — | 18.8% | 55.0x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
HCG since 1 January, against earlier years.
Historical volatility
HCG's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 12.0% |
| FY2022 | 17.0% |
| FY2023 | 18.0% |
| FY2024 | 17.0% |
| FY2025 | 17.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹1,277 Cr |
| Costs | |
| Interest | ₹84 Cr |
| Expenses | ₹1,065 Cr |
| Operating profitOperating Profit | ₹211 Cr |
| Other income and charges | |
| Profit before tax | ₹20 Cr |
| Tax | |
| Net profitNet Profit | ₹4 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹2,604 Cr |
| Equity capitalEquity Capital | ₹139 Cr |
| Reserves | ₹1,052 Cr |
| Borrowings | ₹1,118 Cr |
| Other liabilitiesOther Liabilities | ₹295 Cr |
| AssetsTotal Assets | ₹2,604 Cr |
| Fixed assetsFixed Assets | ₹1,038 Cr |
| Capital work in progressCWIP | ₹23 Cr |
| Investments | ₹696 Cr |
| Other assetsOther Assets | ₹847 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹146 Cr |
| Investing cash flowCash from Investing Activity | -₹347 Cr |
| Financing cash flowCash from Financing Activity | -₹42 Cr |
| Change in cashNet Cash Flow | -₹243 Cr |
Learn while you research
Academy chapters picked for HealthCare Global Enterprises Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 513.0, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read